Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis? Cheng RK, Leedy D, Ruberg FL. J Am Coll Cardiol 2025 Jan 16:S0735-1097(24)10558.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Cheng RK, Leedy D, Ruberg FL. Can Outpatient Worsening Heart Failure Serve as an Endpoint in Clinical Trials of Transthyretin Amyloidosis? J Am Coll Cardiol 2025 Jan 16:S0735-1097(24)10558.
PMID: 39846939